Pyridostigmine in the treatment of orthostatic hypotension [2] (multiple letters)

Clinical Autonomic Research

Volumn 15, Issue 6, 2005, Pages 421-422

  Senard, Jean Michel ^a   Sandroni, Paola ^b  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; NEOSTIGMINE; PYRIDOSTIGMINE;

AUTONOMIC DYSFUNCTION; BLOOD PRESSURE; CHRONIC DRUG ADMINISTRATION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; LETTER; LONG TERM CARE; MUSCLE DISEASE; MYASTHENIA GRAVIS; ORTHOSTATIC HYPOTENSION; PARKINSONISM; URINARY TRACT DISEASE;

EID: 29144464715     PISSN: 09599851     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10286-005-0321-4     Document Type: Letter

References (17)

1. 1. Castro 2002 Braz J Med Biol Res 35 685 12045833 1:CAS:528:DC%2BD38XlsF2msrk%3D Castro RRT, Porphirio G, Serra SM, Nobrega ACL (2002) Cholinergic stimulation with pyridostigmine reduces the QTc interval in coronary heart disease. Braz J Med Biol Res 35(6):685–689
2. 2. Cook 2002 Psychopharmacology 162 186 10.1007/s00213-002-1074-6 12110996 1:CAS:528:DC%2BD38Xmtlertb0%3D 000177067000010 Cook MR, Graham C, Sastre A, Gerkovich MM (2002) Physological and performance effects of pyridostigmine bromide in healthy volunteers: a dose-response study. Psychopharmacology 162:186–192
3. 3. Douchet 1999 Arch Mal Coeur Vaiss 92 711 10410809 1:STN:280:DyaK1MzjvV2qug%3D%3D Douchet MP, Quiring E, Bronner F, Vi-Fane R, Messier M, Chauvin M, Warter JM (1999) Diminution paradoxale des parameters parasympathiques chez les patients myasthéniques. Arch Mal Coeur Vaiss 92:711–717
4. 4. Iwasaki 1988 Acta Neurol Scand 78 236 3227809 1:STN:280:BiaC2cjltVE%3D 10.1111/j.1600-0404.1988.tb03653.x Iwasaki Y, Wakata N, Kinoshita M (1988) Parkinsonism induced by pyridostigmine. Acta Neurol Scand 78:236
5. 5. Kelsall 2004 Occup ENvironn Med 61 1006 1:STN:280:DC%2BD2crotFWlsw%3D%3D Kelsall HL, Sim MR, Forbes AB, Glass DC, McKenzie DP, Ikin JF, Abramson MJ, Blizzard L, Ittak P (2004) Symptoms and medical conditions in Australian veterans of the 1991 GulfWar: relation to immunisations and other GulfWar exposures. Occup ENvironn Med 61:1006–1013
6. 6. Lazartigues E, Freslon JL, Tellioglu T, Brefel-COurbon C, Pelat M, Tran MA, Montastruc JL, Rascol A (1998) Presso rand bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat. Eur J Pharmacol
7. 7. Levin 2003 J Neurol 250 766 12862037 Levin N, Karussis D, Abramsky O (2003) Parkinson’s disease associated with myasthenia gravis. A report of 4 cases. J Neurol 250:766–767
8. 8. Li 2000 Neurotoxicology 21 541 11022862 1:CAS:528:DC%2BD3cXnt1Knu7s%3D 000089582900010 Li L, Gunasekar PG, Borowitz JL, Isom GE (2000) Muscarinic receptor-mediated pyridostigmine-induced neuronal apoptosis. Neurotoxicology 21:541–552
9. 9. Nobrega 2001 Clin Auton Res 11 11 11503945 1:STN:280:DC%2BD3MvlslKquw%3D%3D Nobrega ACL, dos Resi AF, Moraes RS, Bastos BG, Ferlin EL, Ribeiro JP (2001) Enhancement of heart rate variability by cholinergic stimulation with pyridostigmine in healthy subjects. Clin Auton Res 11:11–17
10. 10. Park 1991 Arch Int Pharmacodyn 311 155 1665057 1:CAS:528:DyaK3MXmt1eisLw%3D Park KH, Long JP, Cannon JG (1991) Reversal of antihypertensive agent-induced postural hypotension with physostigmine. Arch Int Pharmacodyn 311:155–165
11. 11. Peden-Adams 2004 Immunopharmacol Immunotoxicol 26 1 15106728 1:CAS:528:DC%2BD2cXitVanurY%3D Peden-Adams MM, Dudley AC, EuDaly JG, Allen CT, Gilkenson GS, Keil DE (2004) Pyridostigmine bromide (PYR) alters immune function in B6C3F1 mice. Immunopharmacol Immunotoxicol 26:1–15
12. 12. Rowsey 2002 J Appl Physiol 92 789 1:CAS:528:DC%2BD38XhtlSqu78%3D Rowsey PJ, Yang YL, Gordon CJ (2002) Peripheral cholinergic pathway modulates hyperthermia induced by stress in rats exposed to open-field stress. J Appl Physiol 92:789–794
13. 13. Sandroni 2005 Clin Auton Res 15 51 10.1007/s10286-005-0225-3 15768203 Sandroni P, Opfer-Gehrking TL, Singer W, Low PA (2005) Pyridostigmine for treatment of neurogenic orthostatic hypotension: a follow-up survey study. Clin Auton Res 15:51–53
14. 14. Schumm 2002 Psychol Rep 90 707 12090498 Schumm WR, Reppert EJ, Jurich AP, Bollman SR, Webb FJ, Castelo CS, Stever JC, Kaufman M, Deng LY, Krehbiel M, Owens BL, Hall CA, Brown BF, Lash JF, Fink CJ, Crow JR, Bonjour GN (2002) Pyridostigmine bromide and the long term subjective health status of a sample of over 700 male Reserve Component GulfWar era Veterans. Psychol Rep 90:707–721
15. 15. Serra 2001 Arq Bras Cardiol 76 279 10.1590/S0066-782X2001000400002 11323731 1:STN:280:DC%2BD3MzktFSmsA%3D%3D Serra SM, RVC Costa, Bastos BG, Santos KB, Ramalho SHR, Nobrega ACL (2001) Exercise stress testing in healthy subjects during cholinergic stimulation after a single dose of pyridostigmine. Arq Bras Cardiol 76:279–284
16. 16. Singer 2003 J Neurol Neurosurg Psychiatry 74 1294 10.1136/jnnp.74.9.1294 12933939 1:STN:280:DC%2BD3szps1WqtQ%3D%3D Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA (2003) Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry 74(9):1294–1298
17. 17. Wacks 1990 Am J Kidney Dis 16 76 2368710 1:STN:280:By%2BA3MzntVA%3D Wacks I, Oster JR, Perez GO, Kett DH (1990) Spurious hyperchloremia and hyperbicarbonatemia in a patient receiving pyridostigmine bromide therapy for myasthenia gravis. Am J Kidney Dis 16(1):76–79